vTv Therapeutics Q2 2024 EPS $(0.81)
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics reported a Q2 2024 EPS of $(0.81), indicating a significant loss for the quarter.
August 08, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
vTv Therapeutics reported a Q2 2024 EPS of $(0.81), indicating a significant loss for the quarter.
The reported EPS of $(0.81) is a significant loss, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100